Matsuzakia S, Matsuzakia S, Chang EJ, et al. - Researchers investigated women with disseminated peritoneal uterine leiomyosarcoma (uLMS) who underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for their perioperative and survival outcomes. They conducted a comprehensive systematic review of literature using multiple public search engines, PubMed, Scopus, and the Cochrane Library, in compliance with the PRISMA guidelines, and identified 10 studies meeting the inclusion criteria, including 8 case series (n = 28) and 2 original articles (n = 47). Of these 75 patients, 68 (90.7%) had uLMS and received cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). They observed an intraoperative mortality rate of 1.3%, and a postoperative mortality rate of 2.7% (4.0% total mortality rate). A perioperative complication (grade ≥ 3) rate of around 25% was noted for cytoreductive surgery and HIPEC. Survival rate was higher in correlation with providing melphalan HIPEC regimen vs cisplatin-based regimen.